DAC Accession Contact Person Email Access Information
EGAC00001000000 Data Sharing datasharing@sanger.ac.uk http://www.ebi.ac.uk/ega/dacs/EGAC00001000000

This DAC controls 227 datasets:

Dataset Accession Technology Samples Descriptionsort descending
EGAD00001001014 Illumina HiSeq 2000; 2597
EGAD00001001015 Illumina HiSeq 2000; 76
EGAD00001001889 HiSeq X Ten; 9 ***THIS DATA CAN ONLY BE USED FOR NON-COMMERCIAL CANCER RESEARCH*** Sequencing of organoid cell lines derived from oesophageal tumour sections taken from patients diagnosed with primary oesophageal cancer who underwent tumour resection surgery.
EGAD00001001846 HiSeq X Ten; 4 2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation.
EGAD00001000082 Illumina HiSeq 2000;ILLUMINA, Illumina Genome Analyzer II;ILLUMINA 42 20 Matched Pair Breast Cancer Genomes
EGAD00001003248 Illumina MiSeq;ILLUMINA 36 A BRAF V600E colorectal organoid which is sensitive to MAP kinase inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a combination of Trametinib, Dabrafenib and Cetuximab. Single cell derived organoids were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors from a screen in 2 2D BRAF V600E colorectal cell lines. Pools of resistant clones were also sequenced.
EGAD00001000948 Illumina HiSeq 2000; 6 A comparison of the somatic variation present in a primary colorectal tumour and three different liver metastases from the same patient.
EGAD00001000149 Illumina HiSeq 2000 2 A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome
EGAD00001000301 Illumina HiSeq 2000; 1 A couple of previously characterized and sequenced libraries will be repeated using a couple of differing size selection criteria and skim sequenced using an Illumina HiSeq. The resulting sequence will be analyzed to determine the optimal DNA library size for our specific downstream analysis.
EGAD00001003425 Illumina MiSeq;ILLUMINA 177 A EGFR mutant NSCLC cell line which is sensitive to AZD9291 inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a AZD9291. Single cell derived colonies were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors hypothesised from currently available literature. This dataset contains all the data available for this study on 2017-07-05.
EGAD00001001879 Illumina HiSeq 2000; 30 A pilot to establish the feasability of using a custom Agilent targeted pulldown of 110 genes implicated in colorectal tumourigensis to sequence for driver mutations in a set of 30 FFPE colorectal adenomas. If successful, we propose to sequence an additional 350 adenomas as part of a MRC research study in order to define the pattern of driver mutations across the spectrum of pathological subtypes including coventional adenomas, serrated adenomas and hyperplastic polyps
EGAD00001000089 Illumina Genome Analyzer II 20 Acute Lymphoblastic Leukemia Exome sequencing
EGAD00001000104 Illumina Genome Analyzer II 97 Acute Lymphoblastic Leukemia Exome sequencing 2
EGAD00001000116 Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000; 61 Acute Lymphoblastic Leukemia Sequencing
EGAD00001000095 Illumina Genome Analyzer II 9 Acute Myeloid Leukemia Sequencing

Pages

DAC description